Avadel Pharmaceuticals plc shareholders have approved the acquisition by Alkermes plc.
The resolutions required for the Proposed Transaction were successfully passed at the scheme meeting and extraordinary general meeting.
Details of the approval and voting results have been disclosed in the Definitive Proxy Statement filed with the SEC.
Scheme Meeting Proposal Approved
Shareholders voted to agree to the Scheme Meeting Proposal at Avadel's Scheme Meeting.
Scheme Approval Proposal Passed
Shareholders authorized the directors of Avadel to carry out the Scheme and approved the related actions at the EGM.
Articles of Association Amendment Proposal Supported
Shareholders approved the amendment to the Articles of Association at the EGM for issuance of new shares.
Compensation Proposal Ratified
Shareholders approved the compensatory arrangements between Avadel and its executives for the Proposed Transaction.
- The acquisition by Alkermes marks a significant development for Avadel Pharmaceuticals.
- This move is expected to have implications on Avadel's future strategic direction and product development.
- The successful shareholder approval paves the way for a smooth transition and integration process.
- Investors and industry analysts are closely monitoring the impact of this acquisition on Avadel's market position and future growth potential.
Avadel Pharmaceuticals has received shareholder approval for the acquisition by Alkermes, signaling a new chapter for the company.